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Summary
Background Inhaled longacting β2 agonists improve lung
function and health status in symptomatic chronic obstructive
pulmonary disease (COPD), whereas inhaled corticosteroids
reduce the frequency of acute episodes of symptom
exacerbation and delay deterioration in health status. We
postulated that a combination of these treatments would be
better than each component used alone.
Methods 1465 patients with COPD were recruited from
outpatient departments in 25 countries. They were treated in a
randomised, double-blind, parallel-group, placebo-controlled
study with either 50 µg salmeterol twice daily (n=372), 500 µg
fluticasone twice daily (n=374), 50 µg salmeterol and 500 µg
fluticasone twice daily (n=358), or placebo (n=361) for 
12 months. The primary outcome was the pretreatment forced
expiratory volume in 1 s (FEV1) after 12 months treatment’ and
after patients had abstained from all bronchodilators for 
at least 6 h and from study medication for at least 12 h.
Secondary outcomes were other lung function measurements,
symptoms and rescue treatment use, the number of
exacerbations, patient withdrawals, and disease-specific
health status. We assessed adverse events, serum cortisol
concentrations, skin bruising, and electrocardiograms.
Analysis was as predefined in the study protocol.
Findings All active treatments improved lung function,
symptoms, and health status and reduced use of rescue
medication and frequency of exacerbations. Combination
therapy improved pretreatment FEV1 significantly more than did
placebo (treatment difference 133 mL, 95% CI 105–161,
p<0·0001), salmeterol (73 mL, 46–101, p<0·0001), or
fluticasone alone (95 mL, 67–122, p<0·0001). Combination
treatment produced a clinically significant improvement in
health status and the greatest reduction in daily symptoms. All
treatments were well tolerated with no difference in the
frequency of adverse events, bruising, or clinically significant
falls in serum cortisol concentration.
Interpretation Because inhaled long-acting β2 agonists and
corticosteroid combination treatment produces better
control of symptoms and lung function, with no greater risk
of side-effects than that with use of either component alone,
this combination treatment should be considered for patients
with COPD. 
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Introduction
Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity worldwide. It is characterised by
chronic progressive symptoms, airflow obstruction,1,2 and
impaired health status,3 which is worse in those who have
frequent, acute episodes of symptom exacerbation.4 The
aim of treatment is to prevent and control symptoms and
exacerbations while improving lung function and health
status.5,6 Any new treatment approach should be judged
against these endpoints.
Inhaled long-acting β2 agonists improve airflow
obstruction, control of symptoms, and health status in
patients with COPD over 3–4 months7–14 and have several
potentially beneficial non-bronchodilatory effects.15 The
role of inhaled corticosteroids in COPD management is less
certain.16 These drugs do not change the rate of decline in
lung function,17–20 but can increase postbronchodilator
forced expiratory volume in 1 s (FEV1),17,19 reduce the
number of exacerbations,17,18 and slow the rate of decline in
health status.17 Whether long-acting 2 agonists and inhaled
corticosteroids in combination will result in treatment
effects that are better than those associated with either drug
alone is not clear. Furthermore, we do not know whether
improvements seen in the short term will be maintained
during sustained treatment. To test our hypothesis, we did
a randomised controlled trial over 1 year of combination
treatment with salmeterol and fluticasone versus each of the
components and placebo.
Methods
Patients
We recruited outpatients with COPD from 196 hospitals
in 25 countries. All patients had a baseline FEV1 before
bronchodilation that was 25–70% of that predicted, an
increase of less than 10% of predicted FEV1 30 min after
inhaling 400 µg salbutamol, and a prebronchodilator
FEV1/forced vital capacity (FVC) ratio of 70% or less.21
Patients also had a history of at least 10 pack-years of
smoking (ie, equivalent to 20 cigarettes smoked per day
for 10 years), of chronic bronchitis, at least one episode
of acute COPD symptom exacerbation per year in the
previous 3 years, and at least one exacerbation in 
the year immediately before trial entry that required
treatment with oral corticosteroids, antibiotics, 
or both.
We excluded patients who had respiratory disorders
other than COPD, required regular oxygen treatment, or
had received systemic corticosteroids, high doses of
inhaled corticosteroids (>1000 µg daily beclometasone
dipropionate, budesonide, or flunisolide or >500 µg daily
fluticasone), or antibiotics in the 4 weeks before the 
2 week run-in period before the trial began.
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We obtained approval from local ethics committees at
each participating site, and all patients provided written
informed consent.
Study design
We used a randomised, double-blind, placebo-controlled,
parallel-group design. Recruited patients participated in a
2-week run-in to the trial, a 52-week treatment period
with clinic visits at weeks 0, 2, 4, 8, 16, 24, 32, 40, and
52, and a 2-week post-treatment follow-up. 
We used a randomisation schedule generated by the
patient allocation for clinical trials (PACT) program to
assign patients to study treatment groups. Every
participating centre was supplied with a list of patient
numbers (assigned to patients at their first visit) and a list
of treatment numbers. Patients who satisfied the
eligibility criteria were assigned the next sequential
treatment number from the list. Salmeterol and
fluticasone combination (50/500 µg twice daily),
salmeterol (50 µg twice daily), fluticasone (500 µg twice
daily) and placebo were packaged in identical inhaler
devices. Study drugs were labelled in a way to ensure that
both the patient and the investigator were unaware of the
allocated treatment .
During the 2-week run-in, patients stopped taking
regular inhaled corticosteroids or long-acting 2 agonists.
Inhaled salbutamol was used as relief medication
throughout the study, and regular treatment with
anticholinergics, mucolytics, and theophylline was
allowed. All non-COPD medications could be continued
if the dose remained constant whenever possible, and if
their use would not be expected to affect lung function. If
patients had clinically stable symptoms after 2 weeks, they
were randomised to receive one of the following
treatments: 50 µg salmeterol and 500 µg fluticasone in
combination; 50 µg salmeterol; 500 µg fluticasone; or
placebo, all twice daily, for 52 weeks via a multidose dry-
powder inhaler (Diskus or Accuhaler [GlaxoSmithKline,
Greenford, UK]).
The primary efficacy measure was FEV1 after patients
had abstained from all bronchodilators for at least 
6 h, and from study medication for at least 12 h. Lung-
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Placebo Salmeterol Fluticasone Combination
(n=361) (n=372) (n=374) (n=358)
Withdrawal after randomisation 140 (39 %) 119 (32 %) 108 (29 %)* 89 (25 %)†‡
Age 63·4 (8.6) 63.2 (8.6) 63.5 (8.5) 62.7 (8.7)
Male 269 (75 %) 261 (70 %) 260 (70 %) 270 (75 %)
Current smoker 171 (47 %) 191 (51 %) 198 (53 %) 186 (52 %)
Pack-years smoked 43·4 (22·4) 43·7 (21·9) 41·5 (20·7) 42·0 (22·4)
Previous ICS use 188 (52 %) 183 (49 %) 202 (54 %) 178 (50 %)
Previous LABA use 136 (38 %) 156 (42 %) 148 (40 %) 151 (42 %)
Pretreatment FEV1 (% predicted) 44·2 (13·7) 44·3 (13·8) 45·0 (13·6) 44·8 (14·7)
Reversibility (% predicted FEV1) 4·0 (4·5) 3·7 (4·3) 3·7 (3·9) 4·0 (4·7)
Pretreatment FEV1 (mL) 1266 (467) 1245 (452) 1260 (449) 1308 (532)
Postbronchodilator FEV1 (mL) 1379 (476) 1346 (463) 1363 (460) 1419 (549)
Pretreatment FVC (mL) 2500 (800) 2386 (751) 2443 (781) 2537 (838)
PEF L/min 243 (89) 235 (90) 246 (90 ) 247 (93)
SGRQ score 47·1 (16·5) 48·7 (17·1) 49·8 (15·8) 47·1 (15·7)
Median use of relief medication per day (range) 2·7 (0–17) 2·9 (0–14) 2·8 (0–15) 2·7 (0–11)
Mean number awakenings per week 3·5 (5·3) 3·5 (6·1) 3·5 (4·9) 2·8 (4·9)
ICS=inhaled corticosteroids. LABA=longacting 2 agonist. FEV1=forced expiratory volume in 1 s. FVC=forced vital capacity. PEF=peak expiratory flow. 
SGRQ=St George’s Respiratory Questionnaire. Data are number (%) or mean (SD) unless otherwise indicated. *p=0·007 vs placebo. †p=0·0001 vs placebo. ‡p=0·033
vs salmeterol. 
Table 1: Patients’ demographic data and baseline characteristics
1974 patients recruited
1465 patients randomised
         to receive treatment
361 received placebo
221 reached primary
       endpoint
253 reached primary
       endpoint
266 reached primary
       endpoint
269 reached primary
       endpoint
361 withdrew
    68 adverse event
    16 consent withdrawn
    10 protocol violation
    18 lack of efficacy
      6 lost to follow-up
      7 non-compliance
      3 inclusion criteria
    12 other
119 withdrew
    61 adverse event
    13 consent withdrawn
    13 protocol violation
      5 lack of efficacy
      8 lost to follow-up
      5 non-compliance
      3 inclusion criteria
    11 other
108 withdrew
    55 adverse event
    11 consent withdrawn
      5 protocol violation
      7 lack of efficacy
      8 lost to follow-up
    11 non-compliance
      3 inclusion criteria
      8 other
 89 withdrew
    46 adverse event
      6 consent withdrawn
    12 protocol violation
      2 lack of efficacy
      8 lost to follow-up
      5 non-compliance
      4 inclusion criteria
      6 other
372 received salmeterol
       (50 g twice daily)
374 received fluticasone
       (50 g twice daily)
358 received salmeterol and
       fluticasone combination
       (50/500 g twice daily)
509 patients withdrew
Figure 1: Trial profile
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function tests were done in the clinic: pretreatment FVC,
and postbronchodilator FEV1 and FVC were measured at
each visit. Postbronchodilator measurements were made
30 min after inhalation of 400 µg of salbutamol. All
spirometry measurements were done at the same time of
day for all patients, with the same spirometer. Every
morning, patients used daily record cards to record the
highest of three peak expiratory flow values measured
with a mini-Wright peak flow meter (Clement Clarke
International Harlow, UK) before medication.
Every morning, patients recorded the number of times
they used relief medication, their symptom scores, and
the number of night-time awakenings for the previous 
24 h. Symptoms were scored as: breathlessness, 0 (none)
to 4 (breathless at rest); cough, 0 (none) to 3 (severe);
sputum production, 0 (none) to 3 (severe); sputum
colour, 0 (no sputum produced) to 4 (dark yellow or
green).
The occurrence of acute exacerbations of COPD
symptoms was investigated at every clinic visit.
Exacerbations were defined a priori as a worsening of
COPD symptoms that required treatment with
antibiotics, oral corticosteroids, or both. Episodes that
required corticosteroid treatment or hospital admission
were noted separately. Health status was assessed with the
St George’s Respiratory Questionnaire at weeks 0, 2, 4, 8,
24, and 52. In the 22 non-English speaking countries we
used a validated translation of this questionnaire. 
Adverse event information was obtained at every 
clinic visit by recording spontaneously reported
complaints from patients and asking general questions
about medical troubles and concomitant medication.
Morning (0800–1000 h) cortisol concentrations in serum
were measured after fasting at weeks 0, 24, and 52. At
every visit we noted the number of bruises on the volar
side of the forearms that had a diameter greater than 
5 cm. All patients had 12-lead electrocardiography at
weeks 0, 24, and 52, and investigators categorised the
results as normal, abnormal but not clinically significant,
or abnormal and clinically significant.
Statistical analysis
We estimated that a sample size of 300 patients per
treatment group would be needed to obtain data for 
250 patients so as to detect a 0·10 L difference in FEV1 at
the 5% significance level with 90% power, assuming an
SD of 0·35 L for FEV1. We analysed pretreatment FEV1
using repeated measures analysis.22 Time was included as
a categorical parameter and an unstructured variance-
covariance matrix was fitted with SAS proc mixed
software version 6.12. We also used these methods to
analyse other lung function variables and questionnaire
scores. We analysed log-transformed serum cortisol
concentrations, morning peak expiratory flow, and mean
symptom score during weeks 1–52 using analysis of
covariance. The number of exacerbations was analysed by
a maximum likelihood Poisson regression, with the
amount of time a patient had had treatment as an offset
variable. Covariates used for analyses, where applicable,
were age, sex, country, baseline value (such as FEV, and
FVC at randomisation), and smoking status. Interactions
of treatment with all covariates were tested for
pretreatment FEV1, exacerbations, and health status
questionnaire scores. For use of rescue medication, the
median data for weeks 1–52 were analysed using the van
Elteren extension to the Wilcoxon rank sum test,23
stratified by smoking status, and the confidence limits
calculated with the Hodges-Lehman method.24 The
number of withdrawals was analysed with the Cochran-
Mantel-Haenszel test, stratified by smoking status, and
time to withdrawal was analysed with Cox’s proportional
hazards model.
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Figure 2: Effect of treatment on lung function measurements and
health status 
Raw mean changes from baseline are shown. A, prebronchodilator FEV1. 
B, postbronchodilator FEV1. C, daily peak expiratory flow. D, health status—
the fall in St George’s score represents an improvement in health status.
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Role of the funding source
The study sponsor, GlaxoSmithKline, was involved
together with the principal investigators in the 
study design; the collection and analysis of data, which
was made freely available to all the principal
investigators; and the decision to submit the paper for
publication.
Results
We recruited 1974 patients from 196 centres in 25
countries, of whom 1465 received treatment (figure 1).
Demographic data, baseline characteristics, and
compliance did not differ between groups, but the
withdrawal rate did. Significantly fewer patients
withdrew from the combination and fluticasone 
groups than from placebo and salmeterol groups 
(table 1). The main reason for differences in withdrawal
was presence of adverse events. Patients 
in the combination group had a slightly higher mean
prebronchodilator and postbronchodilator FEV1 and
fewer mean awakenings per week than did those in 
other groups. These minor imbalances in baseline 
data were accounted for in the statistical analyses 
since both baseline FEV1 and mean night awakenings
per week were used as covariates in analyses where
appropriate.
The three active treatments increased pretreatment
FEV1 significantly compared with placebo (salmeterol/
fluticasone p<0·0001; salmeterol p<0·0001; fluticasone
p=0·0063; figure 2). This improvement was evident by
week 2 and was sustained throughout treatment. The
rise in FEV1 associated with combination therapy was
significantly greater than with either of its components
separately (table 2, figure 2). By week 52, pretreatment
FEV1 in the combination group had increased by 10%
compared with 2% in both the salmeterol and
fluticasone groups, and had fallen by 3% in the placebo
group. We noted the same trend for the other lung-
function variables (figure 2). The treatment-by-
smoking-status interaction for prebronchodilator FEV1
was not significant (p=0·134), indicating that the
difference between the treatment groups was unaffected
by whether the participant continued to smoke, or not.
Furthermore, the effects of treatment were not biased
by unbalanced changes in smoking status between the
treatment groups. During the 12-month study period, a
total of 103 patients (6–7% in each treatment group)
changed their smoking habit, with most of these giving
up smoking.
Compared with placebo, all active treatments
significantly reduced the number of exacerbations per
patient per year and the number of exacerbations that
needed treatment with oral corticosteroids (table 3).
The rate of exacerbations fell by 25% in the
combination group (p<0·0001) and by 20% (p=0·0027)
and 19% (p=0·0033) in the salmeterol and fluticasone
groups, respectively, compared with placebo. The
treatment effect was more pronounced in patients 
with severe disease (ie, a baseline FEV1 <50% of
predicted), who showed a 30% reduction with the
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Placebo Salmeterol Fluticasone Combination
(n=361) (n=372) (n=374) (n=358)
Pretreatment FEV1 (mL)
Adjusted mean 1264 (11) 1323 (11)* 1302 (11)† 1396 (11)
Treatment difference‡ 133 73 95
(95% CI) (105–161) (46–101) (67–122)
p‡ <0·0001 <0·0001 <0·0001
Postbronchodilator FEV1 (mL)
Adjusted mean 1408 (11) 1436 (11) 1454 (11)§ 1484 (11)
Treatment difference‡ 76 48 31 
(95% CI) (47–106) (19–77) (2–60)
p‡ <0·0001 0·0014 0·039
Pretreatment FVC (mL)
Adjusted mean 2439 (19) 2525 (19)¶ 2500 (18)|| 2594 (19)
Treatment difference‡ 155 68 94
(95% CI) (106–204) (20–117) (46–142)
p‡ <0·0001 0·006 <0·0001
PEF (L/min) 
Adjusted mean 242 (2·1) 257 (2·0)* 255 (2·0)* 274 (2·1)
Treatment difference‡ 32 17 18
(95% CI) (26–37) (11–22) (13–24)
p‡ <0·0001 <0·0001 <0·0001
Data are mean (SE). *p<0·0001 vs placebo; †p=0·0063 vs placebo; ‡vs combination treatment §p=0·002 vs placebo; ¶ p=0·0004 vs placebo; || p=0·013 vs placebo. 
Table 2: Effect of 52 weeks’ treatment on lung function 
Placebo Salmeterol Fluticasone Combination
(n=361) (n=372) (n=374) (n=358)
Total exacerbation rate
Mean rate per patient per year (SD) 1·30 1·04* 1·05* 0·97
Treatment ratio† (95% CI) 0·746 0·930 0·925
(0·643–0·865) (0·801–1·080) (0·797–1·073)
p† <0·0001 0·345 0·304
Rate of exacerbations requiring oral corticosteroids
Mean rate/patient/year 0·76 0·54‡ 0·50§ 0·46
Treatment ratio† 0·607 0·853 0·925
(0·500–0·736) (0·699–1·039) (0·755–1·133)
p† <0·0001 0·115 0·453
*p=0·003 vs placebo. †vs combination treatment. ‡p=0·0003 vs placebo. §p=0·0001 vs placebo.
Table 3: Effect of 52 weeks’ treatment on exacerbation rate
For personal use. Only reproduce with permission from The Lancet Publishing Group.
combination compared with placebo, as against a 
10% reduction in patients who had a baseline FEV1 that 
was greater than 50% of that predicted. Acute episodes
of symptom exacerbation that required oral cortico-
steroids were reduced by 39% in the combination group
(p<0·0001), 29% in the salmeterol group (p=0·0003),
and 34% in the fluticasone group (p=0·0001),
compared with placebo. There were no significant
differences between active treatments with respect to
their effect on the rate of episodes of symptom
exacerbation (table 3), time to first exacerbation, or
number of hospital admissions. Figure 3 shows the
cumulative risk of acute exacerbations.
Combination treatment significantly reduced
breathlessness and the use of relief medication
compared with placebo, salmeterol, and fluticasone
(table 4). Median number of days without relief
medication was for placebo 0% (range 0–100%),
salmeterol 3% (0–100%), fluticasone 2% (0–100%),
and combination 14% (0–100%) (p<0·0001 vs
placebo, p=0·004 vs salmeterol, p=0·0003 vs
fluticasone). The number of night-time awakenings 
fell significantly in the combination group, compared
with placebo and salmeterol, but not with fluticasone
(table 4). Cough only improved significantly in the
combination group (table 4). 
Only the combination group showed a clinically
significant improvement in health status questionnaire
score by week 52. The raw mean changes in health
status total score were –4·3 (SD 10·8) by week 8 and
–4·5 (12·9) at week 52 (figure 2). The change in SGRQ 
score in the combination group over 52 weeks at the 
end of the study was significantly greater than 
that in both the placebo and fluticasone groups 
(table 4).
All treatments were well tolerated, and there were 
no differences between groups in the number of 
patients reporting an adverse event during treatment
(78–81% across all groups), apart from an increased
frequency of oropharyngeal candidosis (placebo 
2%, salmeterol 2%, fluticasone 7%, combination 
8%). Table 5 shows adverse events that were judged 
to be treatment-related. Most patients (96%) 
had serum cortisol values that were within the reference
range, or that did not change significantly from 
baseline after 24 or 52 weeks of treatment. 13 (4%) 
and 11 (4%) patients in the placebo and salmeterol/
fluticasone groups, respectively, had a change from
within to below the reference range, compared with 
17 (5%) and 19 (6%) in the salmeterol and fluticasone
groups, respectively. None of these changes was
clinically important. After 52 weeks’ treatment, 
mean serum cortisol concentrations rose by 4% in
placebo and 6% in the salmeterol group, whereas 
they fell by 1% with fluticasone and by 3% with 
the combination treatments. The differences between
fluticasone and placebo were significant at weeks 
24 (p=0·035) and 52 (p=0·007), and between combi-
nation and placebo at week 24 (p=0·020). None of the
changes were associated with any clinical effects or signs
of hypoadrenalism.
We noted skin bruises in a maximum of 22 (6%) 
of patients in the placebo group, 20 (6%) in salmeterol,
26 (7%) in fluticasone, and 29 (8%) in the combination
group at any visit. We did not detect any changes 
on echocardiograms that could be attributed to
treatment.
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Figure 3: Cumulative risk of acute exacerbations
Placebo Salmeterol Fluticasone Combination
(n=361) (n=372) (n=374) (n=358)
SGRQ total score
Adjusted mean 46·3 (0·5) 45·2 (0·4) 45·5 (0·4) 44·1 (0·5)
Treatment difference* (95% CI) –2·2 (–3·3 to –1·0) –1·1 (–2·2 to 0·1) –1·4 (–2·5 to –0·2)
p* 0·0003 0·071 0·021
Symptom scores
Cough  1·44 (0·03) 1·36 (0·03) 1·38 (0·03) 1·35 (0·03) 
p* 0·018 0·639 0·340
Breathlessness 1·66 (0·03) 1·59 (0·03) 1·58 (0·03) 1·47 (0·03)
p* 0·0001 0·006 0·010
Sputum production 1·34 (0·03) 1·30 (0·03) 1·33 (0·03) 1·29 (0·03)
p* 0·196 0·687 0·339
Sputum colour 1·36 (0·03) 1·35 (0·03) 1·37 (0·03) 1·32 (0·03)
p* 0·373 0·494 0·250
Median (range) use of relief medications 2 (0–32) 2 (0–14)† 2 (0–11)‡ 1 (0–10)
(per day)
p* <0·0001 0·0001 0·0003
Mean number awakenings per week 3·01 (0·21) 2·94 (0·21) 2·45 (0·21)§ 2·31 (0·21)
p* 0·006 0·011 0·591
SGRQ=St George’s Respiratory Questionnaire. Data are mean (SE), unless otherwise indicated. A negative value represents an improvement in health status.
*vs combination; †p=0·028 vs placebo; ‡p=0·010 vs placebo; §p=0·024 vs placebo.
Table 4: Effect of 52 weeks’ treatment on health status and symptoms
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Discussion
Ideally, any new treatment for COPD should improve
one or more of the endpoints outlined in the GOLD
(Global Initiative for Chronic Obstructive Lung
Disease) management protocol25—symptoms, health
status, and frequency of exacerbation. These effects
should be sustained and better than those of existing
treatments. Many treatment trials in COPD have only
lasted 3–6 months,18,26 or if longer, they have compared
only one active treatment with placebo. Our trial has
compared commonly prescribed agents from different
therapeutic classes for a sufficient time to see changes in
a range of clinically relevant outcomes. Our results
confirm that active treatment is better than placebo. A
combination of different types of treatment produces
benefits across a range of endpoints that translate into a
clinically noticeable benefit for patients, as indicated by
the health status data.
Consistent changes were seen in the pretreatment
FEV1, suggesting a drug effect before the first dose taken
in the day. Both salmeterol and fluticasone produced
small but significant improvements in FEV1 in keeping
with previous findings,7,17,18 but combination treatment
was significantly more efficacious than either placebo or
the individual components. Postbronchodilator FEV1
improved after fluticasone, as also noted by
investigators in the ISOLDE study.17 Patients in the
combination group had the lowest bronchodilator
responsiveness (ie, the change between pretreatment
and post-treatment FEV1), suggesting that part of the
pretreatment effect in patients in the combination group
was caused by the bronchodilatory effects of salmeterol
taken 12 h previously. However, despite this effect,
patients in the combination group had a significantly
higher postbronchodilator FEV1 than with either agent
alone. Data for FVC showed much the same trend as
that seen for FEV1, but are more relevant to improved
exercise performance in COPD. Finally, the multiple
daily readings of peak expiratory flow showed a
sustained improvement throughout the year, which was
significantly greater in the combination group, and
evident within 1 week of randomisation. These early
changes in lung function could provide a useful guide to
subsequent patient benefit, but this indicator has not
yet been formally tested.
Improved lung function was associated with
reductions in the number and type of symptoms
recorded in the daily diary cards. Although scores for
cough and sputum did not change greatly,
breathlessness was reduced by both salmeterol and
fluticasone but significantly more so with combination
treatment. Much the same pattern was seen with rescue
treatment, and in the amount of sleep disruption. These
data represent daily recordings for 1 year in every
patient, and confirm the sustained nature of the clinical
benefits. Health status measurement provides an
integrated assessment of the effect of COPD on
patients’ health, and has been widely validated.27,28 A 4-
unit reduction in total St George’s respiratory
questionnaire score is associated with both subjective
and objective improvement, such as the ability to walk
further and less perceived breathlessness before and
after exercise.12,29,30 This improvement was achieved by
patients in the combination treatment group after 
12 months, but not by those who received single-drug
treatment or placebo. The speed of change in health
status was less striking than with lung-function tests but
was still evident by 8 weeks, in keeping with other data
about long-acting 2 agonists.9 The lower than expected
frequency of acute episodes of symptom exacerbation in
patients who received placebo might explain some of
the health status improvement.
All active treatments were associated with a lower rate
of exacerbations than was placebo. Despite differences
in definition, we noted a self-reported exacerbation rate
that was similar to that in other trials—ie, 1·3 per year
with placebo.4,17 Combined treatment reduced the total
exacerbation rate by 25% and exacerbations that
required oral corticosteroids by 39%, which were all
significant changes compared with placebo. Although
these reductions were not statistically significant when
compared with monotherapy, there was a trend in
favour of the combination group which became more
pronounced with increasing COPD severity. Despite
our selection criteria, we saw substantially fewer
exacerbations than expected (46% of patients did not
have such an incident), which significantly reduced the
power of the study to show a difference. The low rate of
acute episodes might be attributable to regression to the
mean in exacerbation number or an effect of improved
care associated with clinical trials, but suggests that a
study of longer duration and with a larger number of
participants would be needed to show a difference. All
active therapies were well tolerated, and there was no
evidence of important cardiac side-effects with
salmeterol, or any unanticipated problems with
fluticasone. There were minor changes in cortisol
secretion with fluticasone monotherapy and with
combination treatment, which did not differ from those
previously reported.17,18
The reasons why combination treatment proved to 
be most effective remain speculative. Results from
research in asthma suggest that long-acting β2
adrenoceptor agonists can enhance the anti-
inflammatory effect of corticosteroids.31 Although the
absolute changes in lung function induced by
combination treatment in our study were modest, they
did happen rapidly, and were noticeable after 2 weeks.
Such improvements could be sufficient to allow
improvement in exercise tolerance and reduce the
perceived severity of an exacerbation, and hence the
number of episodes reported. Both factors are
important determinants of health status.17,32 The
additional effect of an inhaled corticosteroid on
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Placebo Salmeterol Fluticasone Combination
(n=361) (n=372) (n=374) (n=358)
Any treatment-related event 49 (14%) 46 (12%) 70 (19%) 58 (16%)
Oropharyngeal candidosis 5 (1%) 5 (1%) 23 (6%) 22 (6%)
Candidosis in unspecified site 0 2 (<1%) 8 (2%) 1 (<1%)
Oral inflammation or nausea and vomiting 8 (2%) 3 (<1%) 3 (<1%) 4 (1%)
COPD exacerbation 19 (5%) 8 (2%) 10 (3%) 9 (3%)
Cough, breathing disorder, 
or lower respiratory infection 6 (2%) 7 (2%) 6 (2%) 3 (<1%)
Throat infection or hoarseness 8 (2%) 8 (2%) 16 (4%) 15 (4%)
Headaches, tremor, or vertigo 4 (1%) 10 (3%) 2 (<1%) 4 (1%)
Table 5: Treatment-related adverse events
For personal use. Only reproduce with permission from The Lancet Publishing Group.
postbronchodilator FEV1 has been noted before.17
 receptor numbers can be upregulated with
corticosteroids, and the combination is more effective in
reducing induced interleukin 8 release from airway
smooth muscle.33 Whether this mechanism is important
in COPD remains to be established
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The right word
G Burnham
Uses of error
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA (G Burnham MD)
Error is a grim idea, with connotations of bias,
misjudgment, and increasingly, of liability. Yet the
inadvertent and the fortuitous have given medicine a
number of its great successes. Many of the errors noted in
this Lancet series have centred on lessons practitioners
have learnt from clinical misjudgments. Fewer have come
from public health or population-based endeavours. As
with clinical medicine, these chance occurrences are both
prevalent and underacknowledged.
When ivermectin was first being tested for effectiveness
in onchocerciasis we set out to measure its adverse
reactions when given as mass treatment. The three-year
study was conducted in an endemic area of Malawi using
a double blind, placebo-controlled design. For these
multi-site trials, the World Health Organization had set
explicit criteria for exclusion of subjects from the study.
Because of the potential for ivermectin to cross the blood-
brain barrier in mice, it was thought that persons with a
history of epileptic fits should not receive treatment. This
was an important consideration for us since epilepsy was
quite common in this part of Malawi, and our hospital
ran a heavily patronised outreach service for its
treatment. 
Instructions for potential ivermectin recipients were
translated into the vernacular, back translated, and then
pilot tested in a nearby non-study site for comprehension.
Changes were made as necessary to instructions. The
importance of epilepsy as a reason for not participating
was specifically noted in the verbal instructions to
potential participants. 
After the first round of treatment it became evident
that almost no one had been excluded from treatment
because of a history of epilepsy. Pursuing this it was
discovered that the specific word used for epilepsy was
not recognised in the study villages even though the
language was the same as in the pilot area where the
instructions had been pre-tested. In a hurried follow-up
we identified some 80 persons with epilepsy who had
been unintentionally treated with ivermectin. Further
investigations in this cohort with a history of epilepsy
revealed that no fits had followed treatment. The cohort
was then followed through the two subsequent annual
treatment rounds during which there was no association
between receiving treatment and having fits. On the basis
of these Malawi findings, a history of epilepsy was
dropped as a reason for excluding treatment in the
subsequent ivermectin mass-treatment programmes for
onchocerciasis. The outcome from this error of words has
been that tens of thousands of epileptics living in 37
countries where onchocerciasis is endemic have been
treated regularly as a prevention against this physically
disabling and potentially blinding disease. This is another
reminder that a study may yield important findings aside
from the answering of the original research questions.
